Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julius L Katzmann

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Current Cardiology Reports|June 23, 2019
New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular DiseaseJulius L Katzmann, Ulrich Laufs
Current Opinion in Lipidology|January 26, 2024
PCSK9-directed therapies: an updateJulius L Katzmann, Ulrich Laufs
Innere Medizin (Heidelberg, Germany)|April 8, 2022
[Modern lipid-lowering drugs-A means to counter the problem of undertreatment?]Julius L Katzmann, Ulrich Laufs
Metabolites|January 20, 2022
Gene Therapy Targeting <i>PCSK9</i>Julius L Katzmann, Arjen J Cupido, Ulrich Laufs
Frontiers in Physiology|December 11, 2020
PCSK9 Inhibition: Insights From Clinical Trials and Future ProspectsJulius L Katzmann, Ioanna Gouni-Berthold, Ulrich Laufs
Plos One|October 27, 2022
Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular riskJulius L Katzmann, Christian Becker, Aikaterini Bilitou, et al.
Scientific Reports|January 3, 2024
LDL cholesterol target attainment in cardiovascular high- and very-high-risk patients with statin intolerance: a simulation studyJulius L Katzmann, Paulina E Stürzebecher, Silvia Kruppert, et al.
Herz|April 21, 2022
[Update on PCSK9 inhibition]Julius L Katzmann, Florian Custodis, Stephan H Schirmer, et al.
Patient Preference and Adherence|December 28, 2018
Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular riskJulius L Katzmann, Felix Mahfoud, Michael Böhm, et al.
European Journal of Internal Medicine|February 1, 2025
Lipoprotein(a) and prothrombotic effects: Evidence from a genetic association studyElena Olmastroni, Julius L Katzmann, Federica Galimberti, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Current Cardiology Reports|June 23, 2019
New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular DiseaseJulius L Katzmann, Ulrich Laufs
Current Opinion in Lipidology|January 26, 2024
PCSK9-directed therapies: an updateJulius L Katzmann, Ulrich Laufs
Innere Medizin (Heidelberg, Germany)|April 8, 2022
[Modern lipid-lowering drugs-A means to counter the problem of undertreatment?]Julius L Katzmann, Ulrich Laufs
Metabolites|January 20, 2022
Gene Therapy Targeting <i>PCSK9</i>Julius L Katzmann, Arjen J Cupido, Ulrich Laufs
Frontiers in Physiology|December 11, 2020
PCSK9 Inhibition: Insights From Clinical Trials and Future ProspectsJulius L Katzmann, Ioanna Gouni-Berthold, Ulrich Laufs
Plos One|October 27, 2022
Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular riskJulius L Katzmann, Christian Becker, Aikaterini Bilitou, et al.
Scientific Reports|January 3, 2024
LDL cholesterol target attainment in cardiovascular high- and very-high-risk patients with statin intolerance: a simulation studyJulius L Katzmann, Paulina E Stürzebecher, Silvia Kruppert, et al.
Herz|April 21, 2022
[Update on PCSK9 inhibition]Julius L Katzmann, Florian Custodis, Stephan H Schirmer, et al.
Patient Preference and Adherence|December 28, 2018
Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular riskJulius L Katzmann, Felix Mahfoud, Michael Böhm, et al.
European Journal of Internal Medicine|February 1, 2025
Lipoprotein(a) and prothrombotic effects: Evidence from a genetic association studyElena Olmastroni, Julius L Katzmann, Federica Galimberti, et al.
Pageof 3